DGIdb - CAPTOPRIL Drug Record

CAPTOPRIL chembl:CHEMBL1560 Approved

Alternate Names:

HYTENEZE 12.5
CAPTOPRIL
LOPRIL
HYTENEZE 25
KAPLON
SQ-14225
ECOPACE
CAPTOMEX
HYTENEZE 50
NOYADA
TENSOBON
SA-333
C09AA01
CAPOTEN
SQ -14225
ACEPRIL
ACEPRESS
CAPTOPRYL
CAPOTEN®
L-CAPTOPRIL
D-3-MERCAPTO-2-METHYLPROPANOYL-L-PROLINE
CAPTOLANE
HYPERTIL
APOPRIL
(2S)-1-[(2S)-2-METHYL-3-SULFANYLPROPANOYL]PYRROLIDINE-2-CARBOXYLIC ACID
CAPTORIL
LOPIRIN
CP
D-2-METHYL-3-MERCAPTOPROPANOYL-L-PROLINE
GARRANIL
TENSOPREL
TENOSBON
CAPTOPRILUM
CESPLON
DILABAR
drugbank:01197
rxcui:1998
pubchem.compound:44093
chembl:CHEMBL1560
chemidplus:62571-86-2

Drug Info:

FDA Approval	1981
Drug Class	small molecule
Drug Indications	Antihypertensive Agents
Drug Categories	enzyme inhibitors
Year of Approval	1981
Drug Class	antihypertensive agents
Drug Categories	agents causing angioedema
Drug Categories	agents causing hyperkalemia
Drug Categories	agents causing muscle toxicity
Drug Categories	antihypertensive agents indicated for hypertension
Drug Categories	drugs causing inadvertant photosensitivity
Drug Categories	oat1/slc22a6 inhibitors
Drug Categories	oat1/slc22a6 substrates
Drug Categories	oat3/slc22a8 substrates
Drug Categories	p-glycoprotein inhibitors
Drug Categories	photosensitizing agents

(6 More Sources)

Publications:

Reinhardt et al., 2002, Cardiac remodelling in end stage heart failure: upregulation of matrix metalloproteinase (MMP) irrespective of the underlying disease, and evidence for a direct inhibitory effect of ACE inhibitors on MMP., Heart
Okada et al., 2008, Captopril attenuates matrix metalloproteinase-2 and -9 in monocrotaline-induced right ventricular hypertrophy in rats., J. Pharmacol. Sci.
Williams et al., 2005, Inhibition of matrix metalloproteinase activity and growth of gastric adenocarcinoma cells by an angiotensin converting enzyme inhibitor in in vitro and murine models., Eur J Surg Oncol
Yamamoto et al., 2008, Inhibitory profiles of captopril on matrix metalloproteinase-9 activity., Eur. J. Pharmacol.
Ferreira de Oliveira F et al., 2016, Pharmacogenetic effects of angiotensin-converting enzyme inhibitors over age-related urea and creatinine variations in patients with dementia due to Alzheimer disease., Colomb Med (Cali)
Kumakura et al., 1988, Role of bradykinin in the vascular permeability response induced by carrageenin in rats., Br. J. Pharmacol.
Tzakos et al., 2006, The molecular basis for the selection of captopril cis and trans conformations by angiotensin I converting enzyme., Bioorg. Med. Chem. Lett.
Marumo et al., 1987, Mechanisms for the inhibition of vasopressin-stimulated water flow by captopril in the toad bladder., Pharmacology
Ogawa et al., 1985, No role for prostaglandins and bradykinin in the autoregulation of renal blood flow., Jpn. J. Pharmacol.
Piepho, 2000, Overview of the angiotensin-converting-enzyme inhibitors., Am J Health Syst Pharm
Song et al., 2002, Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update., Clin Pharmacokinet
Kumakura et al., 1987, Role of bradykinin generating and degrading systems in the vascular permeability response induced with kaolin in rats., J. Pharmacol. Exp. Ther.
Volkan-Salanci B et al., 2009, Impact of renin-angiotensin system polymorphisms on renal haemodynamic responsiveness to acute angiotensin-converting enzyme inhibition in type 2 diabetes mellitus., J Renin Angiotensin Aldosterone Syst
Andújar-Sánchez et al., 2007, Thermodynamic determination of the binding constants of angiotensin-converting enzyme inhibitors by a displacement method., FEBS Lett.
Dietze et al., 1987, [Captopril in hypertensive patients with type II diabetes mellitus]., Herz
Metting et al., 1987, Enzymatic formation of angiotensins II and III in the hindlimb circulation of dogs., Can. J. Physiol. Pharmacol.
Natesh et al., 2004, Structural details on the binding of antihypertensive drugs captopril and enalaprilat to human testicular angiotensin I-converting enzyme., Biochemistry
Felehgari V et al., 2011, ACE gene polymorphism and serum ACE activity in Iranians type II diabetic patients with macroalbuminuria., Mol Cell Biochem
Dalkas et al., 2010, Study of a lipophilic captopril analogue binding to angiotensin I converting enzyme., J. Pept. Sci.
Kiowski et al., 1982, Antihypertensive and renal effects of captopril in relation to renin activity and bradykinin-induced vasodilation., Clin. Pharmacol. Ther.
Suzuki et al., 1981, Converting enzyme inhibition and modulation of plasma renin activity with captopril in anesthetized rats., Arch Int Pharmacodyn Ther
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
O'Toole L et al., 1998, Effect of the insertion/deletion polymorphism of the angiotensin-converting enzyme gene on response to angiotensin-converting enzyme inhibitors in patients with heart failure., J Cardiovasc Pharmacol
Todorov et al., 2003, Trypanosoma cruzi induces edematogenic responses in mice and invades cardiomyocytes and endothelial cells in vitro by activating distinct kinin receptor (B1/B2) subtypes., FASEB J.
Morinelli et al., 2002, Utilization of a radioimmunoassay to detect the generation of Arg-Pro-Pro-Gly-Phe, a stable endproduct of bradykinin metabolism (from cultured rat aortic smooth muscle cells exposed to bradykinin)., Int. Immunopharmacol.
Regoli et al., 1986, Conversion of kinins and their antagonists into B1 receptor activators and blockers in isolated vessels., Eur. J. Pharmacol.
Jacobsen P et al., 1998, Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy., Kidney Int
Mizuiri S et al., 1997, Renal hemodynamic changes induced by captopril and angiotensin-converting enzyme gene polymorphism., Nephron
Hu et al., 1996, Effect of chronic captopril treatment on circulating and tissue renin-angiotensin system in SHR rats., Zhongguo Yao Li Xue Bao
Davis et al., 1996, Substance P and capsaicin-induced mechanical hyperalgesia in the rat knee joint; the involvement of bradykinin B1 and B2 receptors., Br. J. Pharmacol.
Mazzocchi et al., 1985, Effect of somatostatin on the zona glomerulosa of rats treated with angiotensin II or captopril: stereology and plasma hormone concentrations., J. Steroid Biochem.
Brower et al., 2007, Inhibition of matrix metalloproteinase activity by ACE inhibitors prevents left ventricular remodeling in a rat model of heart failure., Am. J. Physiol. Heart Circ. Physiol.
Prontera et al., 1999, Inhibition of gelatinase A (MMP-2) by batimastat and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma., Int. J. Cancer
Yamamoto et al., 2010, Captopril directly inhibits matrix metalloproteinase-2 activity in continuous ambulatory peritoneal dialysis therapy., Clin. Chim. Acta
Byrd et al., 2007, Dipeptidyl peptidase IV deficiency increases susceptibility to angiotensin-converting enzyme inhibitor-induced peritracheal edema., J. Allergy Clin. Immunol.
Liu et al., Modification of cardiac subcellular remodeling due to pressure overload by captopril and losartan., Clin. Exp. Hypertens.
Veerasingham et al., 2005, Increased PI3-kinase in presympathetic brain areas of the spontaneously hypertensive rat., Circ. Res.
Moriyama et al., 1997, Captopril reduced plasminogen activator inhibitor activity in patients with acute myocardial infarction., Jpn. Circ. J.
Thunnissen et al., 2002, Crystal structures of leukotriene A4 hydrolase in complex with captopril and two competitive tight-binding inhibitors., FASEB J.
Lasdun et al., 1989, Inhibition of endopeptidase 24.15 slows the in vivo degradation of luteinizing hormone-releasing hormone., J. Pharmacol. Exp. Ther.
Moretti et al., 1997, Alteration of cytochrome P-450 isozymes by captopril and idrapril in hepatic and renal microsomes of normotensive and spontaneously hypertensive rats., J. Cardiovasc. Pharmacol.
Fu et al., 2005, A reduction of endogenous asymmetric dimethylarginine contributes to the effect of captopril on endothelial dysfunction induced by homocysteine in rats., Eur. J. Pharmacol.
Fan X et al., 2007, Polymorphisms of ACE2 gene are associated with essential hypertension and antihypertensive effects of Captopril in women., Clin Pharmacol Ther
Day JA et al., 2013, Investigating the selectivity of metalloenzyme inhibitors., J Med Chem
Ignjatovic T et al., 2002, Novel mode of action of angiotensin I converting enzyme inhibitors: direct activation of bradykinin B1 receptor., J Biol Chem

CAPTOPRIL ACE

Interaction Score: 1.6

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

Direct Interaction yes

PMIDs:
27546928 2839262 16889963 2442780 3937925 11030016 11929321 3320343 19286758 17618628 3325392 3038284 15236580 20830509 20014331 7042175 6275810 11752352 9869506 12424228 12489813 2875891 9551410 9069453 9863143 8864563

Sources:
NCI TEND PharmGKB TdgClinicalTrial TTD DrugBank GuideToPharmacology ChemblInteractions
CAPTOPRIL ACE2

Interaction Score: 0.95

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17473847

Sources:
PharmGKB
CAPTOPRIL SST

Interaction Score: 0.95

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
2864479

Sources:
NCI
CAPTOPRIL MMP2

Interaction Score: 0.75

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
17308006 10328230 12381651 19057128 15993560 20184869

Sources:
DrugBank
CAPTOPRIL MMP9

Interaction Score: 0.73

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
12381651 19057128 15993560 18501888

Sources:
DrugBank
CAPTOPRIL BDKRB1

Interaction Score: 0.61

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11880373

Sources:
DrugBank
CAPTOPRIL MMP12

Interaction Score: 0.61

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24074025

Sources:
DTC
CAPTOPRIL GNRH1

Interaction Score: 0.61

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
2681686

Sources:
NCI
CAPTOPRIL MYO9B

Interaction Score: 0.61

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10052650

Sources:
NCI
CAPTOPRIL LTA4H

Interaction Score: 0.25

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
12207002

Sources:
DrugBank
CAPTOPRIL SERPINE1

Interaction Score: 0.25

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9152782

Sources:
NCI
CAPTOPRIL CYP19A1

Interaction Score: 0.17

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9268216

Sources:
NCI
CAPTOPRIL AGTR1

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19286758

Sources:
PharmGKB
CAPTOPRIL NOS2

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15680268

Sources:
NCI
CAPTOPRIL DPP4

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17531305

Sources:
NCI
CAPTOPRIL PIK3CG

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15662030

Sources:
NCI
CAPTOPRIL EHMT2

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

DrugBank: DB01197

Version: 5.1.7

Alternate Names:

CAPTOPRIL DrugBank Drug Name

62571-86-2 CAS Number

Acepress Drug Brand

Drug Info:

Drug Type small molecule

Drug Groups approved

Drug Categories ace inhibitors and diuretics

Publications:

Brower et al., 2007, Inhibition of matrix metalloproteinase activity by ACE inhibitors prevents left ventricular remodeling in a rat model of heart failure., Am. J. Physiol. Heart Circ. Physiol.

Prontera et al., 1999, Inhibition of gelatinase A (MMP-2) by batimastat and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma., Int. J. Cancer

Reinhardt et al., 2002, Cardiac remodelling in end stage heart failure: upregulation of matrix metalloproteinase (MMP) irrespective of the underlying disease, and evidence for a direct inhibitory effect of ACE inhibitors on MMP., Heart

TEND: CAPTOPRIL
- Version: 01-August-2011
Alternate Names:

CAPTOPRIL Primary Drug Name

Drug Info:

Drug Class antihypertensive agents

Year of Approval 1981

Publications:
TdgClinicalTrial: CAPTOPRIL
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications Antihypertensive Agents

Drug Class small molecule

FDA Approval 1981

Publications:

NCI: CAPTOPRIL

Version: 14-September-2017

Alternate Names:

C340 NCI drug code

Drug Info:

Publications:

Moretti et al., 1997, Alteration of cytochrome P-450 isozymes by captopril and idrapril in hepatic and renal microsomes of normotensive and spontaneously hypertensive rats., J. Cardiovasc. Pharmacol.

Fu et al., 2005, A reduction of endogenous asymmetric dimethylarginine contributes to the effect of captopril on endothelial dysfunction induced by homocysteine in rats., Eur. J. Pharmacol.

Byrd et al., 2007, Dipeptidyl peptidase IV deficiency increases susceptibility to angiotensin-converting enzyme inhibitor-induced peritracheal edema., J. Allergy Clin. Immunol.

DTC: CAPTOPRIL
- Version: 02-September-2020
Alternate Names:

CHEMBL1560 ChEMBL Drug ID

Drug Info:

Publications:

Day JA et al., 2013, Investigating the selectivity of metalloenzyme inhibitors., J Med Chem

PharmGKB: captopril

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Fan X et al., 2007, Polymorphisms of ACE2 gene are associated with essential hypertension and antihypertensive effects of Captopril in women., Clin Pharmacol Ther

Volkan-Salanci B et al., 2009, Impact of renin-angiotensin system polymorphisms on renal haemodynamic responsiveness to acute angiotensin-converting enzyme inhibition in type 2 diabetes mellitus., J Renin Angiotensin Aldosterone Syst

Ferreira de Oliveira F et al., 2016, Pharmacogenetic effects of angiotensin-converting enzyme inhibitors over age-related urea and creatinine variations in patients with dementia due to Alzheimer disease., Colomb Med (Cali)

TTD: Captopril
- Version: 2020.06.01
Alternate Names:

D0I0EG TTD Drug ID

Drug Info:

Publications:
GuideToPharmacology: 178101850
- Version: 29-September-2020
Alternate Names:

CAPTOPRIL GuideToPharmacology Ligand Name

Drug Info:

Publications:
ChemblInteractions: CHEMBL1560
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL1560
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:

Trial Name	-
Novel drug target	Established target
Direct Interaction	yes

CAPTOPRIL	DrugBank Drug Name
62571-86-2	CAS Number
Acepress	Drug Brand

Drug Type	small molecule
Drug Groups	approved
Drug Categories	ace inhibitors and diuretics

CAPTOPRIL Drug Record

CAPTOPRIL chembl:CHEMBL1560 Approved

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name - Novel drug target Established target Direct Interaction yes

PMIDs: 27546928 2839262 16889963 2442780 3937925 11030016 11929321 3320343 19286758 17618628 3325392 3038284 15236580 20830509 20014331 7042175 6275810 11752352 9869506 12424228 12489813 2875891 9551410 9069453 9863143 8864563

Sources: NCI TEND PharmGKB TdgClinicalTrial TTD DrugBank GuideToPharmacology ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17473847

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 2864479

Sources: NCI

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: 17308006 10328230 12381651 19057128 15993560 20184869

Sources: DrugBank

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: 12381651 19057128 15993560 18501888

Sources: DrugBank

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11880373

Sources: DrugBank

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24074025

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 2681686

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 10052650

Sources: NCI

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: 12207002

Sources: DrugBank

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 9152782

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 9268216

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 19286758

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15680268

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17531305

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15662030

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

DrugBank: DB01197

Alternate Names: CAPTOPRIL DrugBank Drug Name 62571-86-2 CAS Number Acepress Drug Brand

Drug Info: Drug Type small molecule Drug Groups approved Drug Categories ace inhibitors and diuretics

TEND: CAPTOPRIL

Alternate Names: CAPTOPRIL Primary Drug Name

Drug Info: Drug Class antihypertensive agents Year of Approval 1981

Publications:

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

Direct Interaction yes

PMIDs:
27546928 2839262 16889963 2442780 3937925 11030016 11929321 3320343 19286758 17618628 3325392 3038284 15236580 20830509 20014331 7042175 6275810 11752352 9869506 12424228 12489813 2875891 9551410 9069453 9863143 8864563

Sources:
NCI TEND PharmGKB TdgClinicalTrial TTD DrugBank GuideToPharmacology ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
17473847

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
2864479

Sources:
NCI

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
17308006 10328230 12381651 19057128 15993560 20184869

Sources:
DrugBank

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
12381651 19057128 15993560 18501888

Sources:
DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
11880373

Sources:
DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
24074025

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
2681686

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
10052650

Sources:
NCI

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
12207002

Sources:
DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
9152782

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
9268216

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
19286758

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
15680268

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
17531305

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
15662030

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Alternate Names:

CAPTOPRIL DrugBank Drug Name

62571-86-2 CAS Number

Acepress Drug Brand

Drug Info:

Drug Type small molecule

Drug Groups approved

Drug Categories ace inhibitors and diuretics

Alternate Names:

CAPTOPRIL Primary Drug Name

Drug Info:

Drug Class antihypertensive agents

Year of Approval 1981

Drug Info:

Drug Indications Antihypertensive Agents

Drug Class small molecule

FDA Approval 1981

Alternate Names:

C340 NCI drug code

Alternate Names:

CHEMBL1560 ChEMBL Drug ID

Publications:

Day JA et al., 2013, Investigating the selectivity of metalloenzyme inhibitors., J Med Chem

Alternate Names:

D0I0EG TTD Drug ID

Alternate Names:

CAPTOPRIL GuideToPharmacology Ligand Name